Brief: Neurogene Announces First Patient Dosed In Gene Therapy Clinical Trial For Rett Syndrome
18/06/2024 15:06
June 18 (Reuters) - Neurogene Inc NGNE.O :
* NEUROGENE ANNOUNCES FIRST PATIENT DOSED IN HIGH-DOSE
COHORT OF
NGN-401 GENE THERAPY CLINICAL TRIAL FOR RETT SYNDROME
Source text for Eikon: ID:nBw2kRDYDa
Further company coverage: NGNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurogene
See all newsBrief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary
Neurogene Q2 adjusted loss per share misses estimates on employee costs
Neurogene Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kroger, Meta, Sable